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ABSTRACT
Introduction: To determine patient and
rheumatologist preferences for rheumatoid
arthritis (RA) treatment attributes in Spain and
to evaluate their attitude towards shared deci-
sion-making (SDM).
Methods: Observational, descriptive, explora-
tory and cross-sectional study based on a dis-
crete choice experiment (DCE). To identify the
attributes and their levels, a literature review
and two focus groups (patients [P] = 5;
rheumatologists [R] = 4) were undertaken.
Seven attributes with 2–4 levels were presented
in eight scenarios. Attribute utility and relative
importance (RI) were assessed using a condi-
tional logit model. Patient preferences for SDM
were assessed using an ad hoc questionnaire.
Results: Ninety rheumatologists [52.2%
women; mean years of experience 18.1 (SD:
9.0); seeing an average of 24.4 RA patients/week
(SD: 15.3)] and 137 RA patients [mean age:
47.5 years (SD: 10.7); 84.0% women; mean time
since diagnosis of RA: 14.2 years (SD: 11.8) and
time in treatment: 13.2 years (SD: 11.2), mean
HAQ score 1.2 (SD: 0.7)] participated in the
study. In terms of RI, rheumatologists and RA
patients viewed: time with optimal QoL: R:
23.41%/P: 35.05%; substantial symptom
improvement: R: 13.15%/P: 3.62%; time to
onset of treatment action: R: 16.24%/P: 13.56%;
severe adverse events: R: 10.89%/P: 11.20%;
mild adverse events: R: 4.16%/P: 0.91%; mode
of administration: R: 25.23%/P: 25.00%; and
added cost: R: 6.93%/P: 10.66%. Nearly 73% of
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RA patients were involved in treatment deci-
sion-making to a greater or lesser extent; how-
ever, 27.4% did not participate at all.
Conclusion: Both for rheumatologists and
patients, the top three decision-making drivers
are time with optimal quality, treatment mode
of administration and time to onset of action,
although in different ranking order. Patients
were willing to be more involved in the treat-
ment decision-making process.
Keywords: Conjoint analysis; Discrete choice
experiment; Patient perspective; Preferences;
Rheumatoid arthritis; Rheumatologist
perspective; Rheumatology; Share decision
Key Summary Points
Why carry out this study?
Treatment characteristics may determine
its convenience and thereby have impact
on patients’ adherence and health-related
quality of life. Since patients are more
likely to be satisfied and adhere to a
treatment that is in line with their
preferences, a patient-centered care
approach may have significant impact on
treatment outcomes.
Shared decision-making between
physician and patient is a key component
of the patient-centered care. The first step
in shared decision-making is determining
treatment preferences from patients’
perspective.
The aim of this study was to determine the
preferences of patients and
rheumatologists for the attributes of RA
treatments and to evaluate their attitude
towards shared decision-making.
What was learned from the study?
Both for rheumatologists and patients, the
top three decision-making drivers were
found to be time with optimal quality,
treatment mode of administration and
time to onset of action, although in
different ranking order.
For patients, attributes such as time with
optimal quality of life and treatment
mode of administration were found to be
determinants in treatment selection.
Most of RA patients were willing to be
more involved in the treatment decision-
making process. Although nearly 73% of
RA patients indicated that in real-world
practice, they were involved in treatment
decision-making to a greater or lesser
extent, 27.4% of patients were not
involved in the decision, with the
rheumatologists driving the decisions.
INTRODUCTION
Rheumatoid arthritis (RA) is one of the most
prevalent autoimmune chronic inflammatory
diseases [1, 2]. If sub-optimally treated, RA can
lead to joint damage [2], causing different
degrees of disability, loss of quality of life (QoL)
and even increased mortality [3].
In recent years, there have been important
advances in the management and treatment of
RA, which have resulted in better patient prog-
noses [2, 3]. Several efficacious agents are
available for RA treatment, including conven-
tional synthetic (cs) disease-modifying anti-
rheumatic drugs (DMARDs), biologic
(b) DMARDs and targeted synthetic (ts)
DMARDs [4].
RA therapies vary in their mechanisms of
action and in other characteristics, such as route
and frequency of administration or necessity for
laboratory monitoring. These characteristics
may determine the convenience of the therapy
and thereby have impact on patients’ adherence
and QoL. Since patients are more likely to be
satisfied and adhere to a treatment that is in line
with their preferences [5, 6], a patient-centered
care approach, defined as ‘providing care that is
respectful of and responsive to individual
patient preferences, needs, and values, ensuring
that patient values guide all clinical decisions,’
may have significant impact on treatment
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outcomes [7]. In RA, patient and physician
assessment of disease severity and treatment
response often do not align, suggesting that
they focus on different aspects of the disease
[8–11]. Values assigned by patients to their
health status may be strongly driven not only
by clinical aspects such as functional status or
symptoms, but also by their beliefs and expec-
tations. Involving patients in the decision-
making process is crucial, as they must trade off
the perceived benefits of the different treat-
ments with the potential negative conse-
quences. In line with this argument, European
League Against Rheumatism (EULAR) makes the
case for shared decision-making between the
patient and the rheumatologist, ensuring
inclusion of the patient’s preferences when
choosing a suitable medication [12]. In fact,
several studies suggest that the number of
patients who prefer to participate in decisions
during the medical encounter has increased
[13]. Hence, it is becoming increasingly impor-
tant to inform the patient about the different
therapeutic options and to offer them the pos-
sibility to actively participate in the decision-
making process [14], taking into account their
perspective and preferences.
Discrete-choice experiments (DCEs) have
become the most frequently applied approach
to assess patients’ preferences for treatment
characteristics in health care research [15, 16].
In a DCE, individuals are asked to choose their
preferred option among different (hypothetical)
alternatives. This method is based on two
assumptions: (1) that treatments can be descri-
bed in terms of a set of attributes (characteris-
tics) with varying levels and (2) that the priority
given by an individual to treatments depends
on the nature and level of the attributes that
compose them [15]. This methodology has been
used successfully in the past to determine
patient and/or physician preferences for the
attributes of DMARDs in rheumatic diseases
[17–20].
The aim of this study was to determine the
preferences of patients and rheumatologists for
the attributes of RA treatments in Spain and to
evaluate their attitude towards shared decision-
making (SDM).
METHODS
Design
This was an observational, descriptive, explora-
tory and cross-sectional study based on a DCE.
The study was performed within the Spanish
healthcare public system from September 2017
to February 2018. The DCE was conducted in
accordance with International Society for
Pharmacoeconomics and Outcomes Research
(ISPOR) good practice recommendations for
conjoint analysis in healthcare [21].
A steering committee constituted by three
Spanish experts in RA (CDT, JIC, AUA) led the
project.
Study Participants
The study population included RA patients and
rheumatologists with experience in the man-
agement of RA. Study participants were invited
to participate by emails sent by the Spanish
Patient Advocacy Group Coordinadora Nacio-
nal de Artritis (ConArtritis) (RA patients) and
the Spanish Society for Rheumatology (SER)
(rheumatologists).
Patients 18 years or older, on DMARD treat-
ment for at least 12 months and who gave their
consent to participate were included in the
study. The participating rheumatologists had to
have at least 3 years of experience in RA man-
agement and work in the Spanish Health
System.
As per the approach proposed by Orme [22],
the minimum sample size necessary for the DCE
was based on an estimate of proportion. The
criterion of maximum variability was applied,
with a 95% confidence interval and 10%margin
of error. Patient sample size was estimated on
the basis of the adult population in Spain in
2016 (37,408,739) [23] and RA prevalence
(0.5%) [24]. The sample size for the rheuma-
tologists was determined using the estimated
number of rheumatologists practicing in the
public Spanish Health System (629) [25]. A
minimum sample of 96 RA patients and 83
rheumatologists was required.
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Discrete Choice Experiment
Selection of Attributes and Levels
In DCEs, patients choose between two hypo-
thetical treatment alternatives described by
attributes (characteristics) and their corre-
sponding levels (different possible values of the
attributes) [15]. To select the attributes and
levels for the DCE, three consecutive steps were
conducted: (1) literature review; (2) RA patient
focus group discussion; (3) rheumatologist
focus group discussion.
Literature Review
Key terms related to the disease, treatment and
stated-preferences studies were used to search
the international Pubmed/Medline database.
Publications referring to patient and physician
preferences in relation to RA treatment as well
as those that referred to their perspectives on
the management of the disease were consulted.
Articles published in Spanish or English up to 9
March 2016 were reviewed.
The results of the literature review [26] were
used to provide inputs for discussion in both
focus groups.
Focus Groups (Patients and Rheumatologists)
Following the literature review, two focus
groups, one with RA patients and one with
rheumatologists, were used to validate and
assess the relevance of the attributes and levels
identified in the literature as well as to identify
attributes not previously described but that
were relevant to the Spanish RA population.
A total of five RA patients, invited by the
patient advocacy group ‘‘ConArtritis,’’ partici-
pated in the patient focus group. After the
completion of a brief questionnaire on
sociodemographic and clinical characteristics,
the list of attributes and levels derived from the
literature review was presented to the patients
to discuss them. During the discussion, patients
were encouraged to add new attributes and
levels not previously identified in the literature
review, but relevant for them. When all attri-
butes and levels were identified, a ranking
exercise was then performed to determine the
relevance of the attributes and levels proposed.
The interpretation of the qualitative analysis
and the analysis of the ranking exercises
allowed identifying the most important
attributes.
After the patient focus group, one with four
experienced rheumatologists (including the
members of steering committee) was con-
ducted. The objectives of this focus group were
to discuss the relevance of the attributes iden-
tified in the literature review and proposed by
patients from the focus group and define the
attributes and levels to be included in the DCE.
As a result of the literature review and the
two focus groups, seven attributes composed of
two or four levels each were selected (Table 1).
Experimental Design
The combinations of attributes and levels that
defined each treatment pair were determined by
an experimental design developed according to
ISPOR recommendations. The DCE design
encompassed two properties: orthogonality and
balance [21]. The orthogonal design guarantees
that all attribute levels vary independently, and
the balance design ensures that each attribute
level occurs the same number of times. The
pairs of choice (Fig. 1) were generated by the
mix and match algorithm [27]. To avoid domi-
nance between alternatives, the resulting sce-
narios were evaluated for dominated
alternatives.
A total of eight scenarios were created, which
formed a single block. Additionally, an initial
control scenario, in which one treatment was
clearly superior to the other (dominant option),
was included. Participants who answered this
question incorrectly were excluded from anal-
ysis as this indicates that they did not compre-
hend what is required from them in this study
[28].
Survey Instrument
Two online surveys were generated, one for
patients and one for rheumatologists. Both
contained the same DCE choice scenarios and
included an information form and an electronic
informed consent form that had to be read and
accepted before completing the questionnaire.
In addition, both questionnaires initially
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included a series of questions to verify that
participants met the selection criteria.
The rheumatologist questionnaire included a
set of sociodemographic and professional vari-
ables to characterize them. The patient ques-
tionnaire included sociodemographic and
clinical variables, and a Health Assessment
questionnaire (HAQ) to assess the patient’s
functional status [29]. A set of ad hoc questions
was also included to collect the patient’s per-
ception of: (1) the current degree of involve-
ment in treatment decision-making and their
expectations about their involvement [30]; (2)
the satisfaction with the information received
about the disease, current treatment and ther-
apeutic alternatives (Likert scale: 1 = not at all
satisfied; 5 = very satisfied).
Statistical Analyses
Stata version 14 and R version 3.4.1 were used
for the statistical analysis. A value of p\0.05
was considered significant for all statistical tests.
For the descriptive analysis of the qualitative
variables, the relative and absolute frequencies
were calculated, and for the quantitative vari-
ables central tendency and dispersion measures
were used for each group of participants.
To assess the utility and the relative impor-
tance (RI) value given to the attributes of RA
treatments by patients and rheumatologists, a
conditional logit model [31] was used. Respon-
dents who did not select the dominant option
in the control scenario were excluded. Sub-
stantial improvement of RA symptoms, time
with optimal QoL, severe and mild adverse
events and additional cost per month attributes
were linearly transformed. Coefficients
obtained in the conditional logit model repre-
sented the partial utilities, i.e., the preference
for each level within each attribute. A statisti-
cally significant coefficient indicates that the
attribute level influences the respondents’
treatment decisions. The RI of each attribute,
defined as the relative preference weight for the
attribute over all attributes, was calculated as
the quotient between the range of the partial
utility values of the attribute and the sum of the
partial utility values ranges of the whole set of
attributes. The greater the RI among the seven
attributes, the more significant the attribute was
for decision-making.
To evaluate which characteristics of the par-
ticipants influenced decision-making, a hierar-
chical cluster analysis was applied to each group
of participants based on DCE response, i.e., the
scenario selected in each pairs of choice [32].
Since scenario choices were dichotomous, a
Table 1 Attributes and levels used in the discrete choice experiment
Attribute Level 1 Level 2 Level 3 Level 4
Time with optimal QoL 10 years 7 years 5 years 2 years
Substantial improvement of RA
symptoms
9 out of 10 patients 7 out of 10 patients 5 out of 10 patients 3 out of 10
patients
Onset of treatment action 7 days 15 days 1 month 3 months
Severe adverse events 1 out of 100
patients
5 out of 100
patients
Mild adverse events 10 out of 100
patients
30 out of 100
patients
Mode of administration Daily oral Weekly
subcutaneous
Monthly
subcutaneous
Monthly
intravenous
Additional cost/month for treatment 0 10 20 50
QoL quality of life, RA rheumatoid arthritis
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binary distance was applied. Stats and Nbclust
packages were used to determine the optimal
number of clusters [33, 34]. To assess differential
characteristics between the clusters obtained,
sociodemographic and clinical characteristics of
each cluster were compared.
Maximum acceptable risk (MAR) was esti-
mated as the quotient between the utility
associated with a clinical benefit attribute
(substantial improvement of RA symptoms) and
the utility associated with risk (severe adverse
events) [35].
To establish differences between the
patient’s current role in the decision-making
process and their expectations about their
involvement in it, the answers given in the ad
Fig. 1 Example of pair of choice (scenario) presented to RA patients
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hoc questionnaire [30] were compared using
McNemar Bowker’s test [36].
Statement of Ethics Compliance
This study was conducted in accordance with
the principles of the Declaration of Helsinki. It
was developed to ensure that Good Clinical
Practices were observed, in keeping with ICH
Harmonized Tripartite Guideline principles.
The study protocol was submitted to the Span-
ish Agency of Medicines and Medical Devices
and to the Clinical Research Ethics Committee
of Puerta de Hierro-Majadahonda Hospital for
approval. An electronic informed consent form
was read and accepted by all participants before
completing the questionnaire.
RESULTS
Participants’ Characteristics
A total of 94 rheumatologists and 153 RA
patients participated in the study. Due to
incomplete data or incorrect responses to the
control scenario, 4 rheumatologists and 16 RA
patients were excluded from the analysis. A
total of 90 rheumatologists [52.2% women;
mean years of experience in RA 18.1 years (SD:
9.0); seeing an average of 24.4 RA patients/week
(SD: 15.3); 75.6% working in a 200 - 1000 bed
hospital] and 137 RA patients [mean age:
47.5 years (SD: 10.7); 84.0% women; mean time
since diagnosis of RA 14.2 years (SD: 11.8) and
time in treatment 13.2 years (SD: 11.2), mean
HAQ score 1.2 (SD: 0.7)] were included in the
final data analysis (Table 2).
Rheumatologists and Patients’ Preferences
for RA Treatment Attributes
Partial Utilities
The main results of the DCE are shown in
Table 3. Partial utilities denote the importance
assigned to each level within an attribute. A
positive partial utility for an attribute level
indicates a preference for that level over the
reference level, while a negative partial utility
Table 2 Patients sociodemographic and clinical charac-
teristics (n = 137)
Characteristic % of patients or
mean
Age, years, mean (SD) 47.5 (10.7)
Female, % 84
Marital status, %
Married/in a relationship 67.9
Single/separated/divorced/widower 32.1
Level of education, %
Primary school 10.2
Secondary school 32.1
University or higher 51.1
Other 6.6
Employment status, %
Employed, full or part time 47.7
Non-employeda 52.3
Incomes, %
B 2500€/month 83.9
[ 2500€/month 1.5
Unknown/not answered 14.6
Time since diagnosis, years, mean
(SD)
14.2 (11.8)
Time in RA treatment, years, mean
(SD)
13.2 (11.2)
Time in current treatment, years,
mean (SD)
6.2 (7.8)
Mode of administration, %
Oral 21,9
Subcutaneous 18.3
Intravenous 4.4
Oral ? subcutaneous 46.7
Oral ? intravenous 8
Subcutaneous ? intravenous 0.7
Other medicines received/day, mean
(SD)
4.0 (3.4)
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implies a lesser preference. Accordingly, the
higher the partial utility, the greater the pref-
erence. It was not possible to directly compare
partial utility values between attributes. The
attribute levels with a statistically significant
influence in patient/rheumatologist treatment
choice are those with a p value\0.05.
Partial utility of the attributes that were then
linearly transformed (time with optimal QoL,
RA symptoms, severe and mild adverse events
and additional cost per month) must be inter-
preted as one unit increases, 1 year for time with
optimal QoL attribute or a 1% increase in the
proportion of patients for the rest.
Partial utilities of the levels of onset of
treatment action and mode of administration
are negative. This means that these levels are
less preferred than the level of reference: 7 days
and daily oral administration, respectively.
With respect to the onset of treatment action,
1 month is statistically less preferred by patients
and rheumatologists. For the latter, 3 months is
also statistically significant. Notice that for
patients, weekly subcutaneous and monthly
intravenous administrations were statistically
less preferred than daily oral administration,
while for rheumatologists only weekly subcu-
taneous administration was significantly less
preferred.
The probability of mild adverse events rela-
ted to treatment and the associated additional
cost/month were not identified as treatment
decision-making drivers.
Relative Importance
For patients, time with optimal QoL was the
most important attribute in RA treatment
selection followed by mode of administration.
The onset of treatment action, probability of
severe adverse events and additional cost/-
month for treatment had a similar weight in the
choice (RI: 13.6%, 11.2% and 10.7%, respec-
tively). Overall, during the treatment decision-
making process, patients conferred much more
importance to treatment benefit-related attri-
butes (time with optimal QoL ? substantial
improvement of RA symptoms) than to safety
attributes (severe adverse events and mild
adverse events). For rheumatologists, the mode
of administration was the most important
attribute followed by time with optimal QoL
and the onset of treatment action (Fig. 2).
For rheumatologists and patients, treatment
benefits (‘time with optimal QoL’ and ‘sub-
stantial improvement of RA symptoms’)
accounted for 38.6% and 36.6% of the decision,
respectively. For both, these attributes had a
greater weight in the decision than those rela-
ted to safety (patients: 38.7% vs. 12.1%;
rheumatologists: 36.6% vs. 15.1%). It is impor-
tant to note that, for patients, time with opti-
mal QoL provided by the treatment, and its
mode of administration determined 60% of the
decision, while for rheumatologists, the deci-
sion was driven mainly by time with optimal
QoL, mode of administration and onset of
action (Fig. 3).
Cluster Analysis
Based on the choices made in the DCE, i.e.,
scenario selected by participants in each pairs of
choices, the patients’ sample was segmented
into two subgroups (clusters). The analysis of
the patients’ characteristics of the two clusters
only showed statistically significant differences
for the route of administration (p = 0.008)
(Supplementary data Table S1). The estimates of
the utility values of the different routes of
treatment administration according to their
current route of administration suggest that the
current route of treatment administration may
influence patient preference, showing a trend
towards a greater preference for the route of
administration in which the patient is currently
receiving treatment (Supplementary data
Figure S1).
No clusters were identified for
rheumatologists.
Table 2 continued
Characteristic % of patients or
mean
HAQ, mean (SD) 1.2 (0.7)
RA rheumatoid arthritis, SD standard deviation, HAQ
Health Assessment Questionnaire
a Included: long-term sick-leave/disabled/unemployed/
student/household/retired
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Table 3 Patient and rheumatologist DCE results
Attribute Level Patients (n = 137) Rheumatologists (n = 90)
Partial
utility
SE p value* Partial
utility
SE p value*
Time with optimal QoL 1 year 0.244 0.036 < 0.001 0.195 0.045 < 0.001
10 years 2.44 1.951
7 years 1.708 1.366
5 years 1.22 0.976
2 years 0.488 0.39
Substantial improvement of RA
symptoms
1% patientsa 0.003 0.003 0.251 0.015 0.004 < 0.001
9 out of 10 patients
(90%)
0.303 1.35
7 out of 10 patients
(70%)
0.235 1.023
5 out of 10 patients
(50%)
0.168 0.731
3 out of 10 patients
(30%)
0.101 0.438
Onset of treatment action 7 days (ref) 0.000 – – 0.000 – –
15 days - 0.372 0.285 0.193 - 0.602 0.356 0.091
1 month - 0.562 0.255 0.027 - 1.083 0.326 0.001
3 months 0.194 0.275 0.481 - 0.715 0.342 0.036
Severe adverse events 1% patientsa - 0.156 0.058 0.007 - 0.182 0.074 0.014
1 out of 100 patients
(1%)
- 0.156 - 0.182
5 out of 100 patients
(5%)
- 0.781 - 0.908
Mild adverse events 1% patientsa 0.003 0.014 0.856 - 0.014 0.018 0.444
10 out of 100 patients
(10%)
0.025 - 0.139
30 out of 100 patients
(30%)
0.076 – 0.416
Mode of administration Daily Oral (ref) 0.000 – – 0.000 – –
Weekly subcutaneous - 1.394 0.372 < 0.001 - 1.683 0.461 < 0.001
Monthly subcutaneous - 0.375 0.364 0.302 - 0.249 0.442 0.574
Monthly intravenous - 0.956 0.366 0.009 – 0.446 0.458 0.331
Adv Ther (2020) 37:1479–1495 1487
Maximum Acceptable Risk
Differences between patients and rheumatolo-
gist were observed regarding the maximum
acceptable risk. While rheumatologists were
willing to accept an increase of 0.08% of risk to
suffer a severe adverse event for a 1% increase in
the chance of a mayor symptom improvement,
patients’ maximum acceptable risk was lower
(0.02%).
Patients’ Perception of Their Involvement
in Treatment Decision-Making
Statistical differences were observed between
the RA patients’ current role and the expected
role in the treatment decision-making process
(McNemar-Bowker’s test; p\0001). In real-
word practice nearly 73% of patients were
involved in the treatment decision-making to a
greater or lesser extent: 17.8% made the deci-
sion together with their doctor, 23.0%
Fig. 2 Relative importance of attributes for patients and rheumatologists
Table 3 continued
Attribute Level Patients (n = 137) Rheumatologists (n = 90)
Partial
utility
SE p value* Partial
utility
SE p value*
Additional cost/month for
treatment
Additional 1€/month - 0.012 0.007 0.102 – 0.009 0.009 0.296
0 0 0
10 - 0.119 – 0.092
20 - 0.238 - 0.185
50 - 0.594 - 0.462
Bold values indicate that there is statistical significance (p\0.05)
QoL quality of life, RA rheumatoid arthritis, SE standard error
a Refers to a 1% of increase of the proportion of patients
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evaluated the different treatment options toge-
ther with the doctor and the patient was the
one who made the decision, and 31.8% evalu-
ated the different treatment options together
with the doctor but the doctor was the one who
made the decision. However, 27.4% of patients
were not involved in the decision (the
rheumatologists made decisions). Related to
their expectations about their involvement, it is
important to note that 98.5% of patients were
willing to be involved in the treatment deci-
sion-making process, and 71.1% of them would
like to be the ones who make the decision
(Fig. 4).
Patients’ Satisfaction
with the Information Received
The majority of patients were satisfied with the
information received about the disease (60.3%
of patients very satisfied/satisfied) and their
current RA treatment (64.7% very satisfied/sat-
isfied). However, less satisfaction was reported
by patients with information received regarding
therapeutic options (35.8% very satisfied/
satisfied).
DISCUSSION
Patients and physicians have different percep-
tions and beliefs about health and illness [8–11].
Adequate understanding of patients’ health
perceptions and risk tolerance may assist
physicians in the decision-making process at
the time of the clinical encounters by helping
them take into account benefit-risk ratios that
are important to patients [11]. Therefore, in
recent years, the healthcare systems in devel-
oped countries have been evolving into a
patient-centered care model, in which patients
take a more active role in making decisions that
affect them [37], promoting their involvement
in the healthcare decision-making process.
Their participation can occur at multiple levels:
individual (SDM), policy (patient expert on
panels) and commissioning (incorporating
patient preferences in health technology
assessment or health state evaluation) [16].
Stated preference studies, such as DCE, are
increasingly advocated as one of the most reli-
able and valid techniques available for quanti-
fying preferences in health care [15, 16].
In RA, the treat-to-target approach has led
health care professionals to focus on inflam-
matory disease, whereas patients are mainly
Fig. 3 Relative importance of attributes for patients and rheumatologists
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concerned about pain and fatigue reduction
and maintaining physical and mental function
[38]. Better knowledge of patients’ preferences
may help healthcare professionals improve dis-
ease management. By providing information
related to patients’ most salient concerns,
treatment selection can be in line with their
preferences and therefore, improve their satis-
faction and adherence to treatment.
Several studies have investigated preferences
of RA patients [17–20, 39–43]; however, none of
them include an attribute related to treatment
benefits defined as time with optimal QoL.
There is ample evidence that RA negatively
impacts patients’ QoL [44]. In fact, previous
works have found that many RA patients value
QoL more than disease-related variables such as
inflammatory biomarkers or joint counts [45].
Therefore, it is not surprising that our results
pointed out ‘time with optimal QoL’ as one of
the most important attributes, achieving a
higher relative importance than ‘substantial
improvement of RA symptoms.’ These results
suggest that patients place greater value on
medium- to long-term improvement than a
one-off improvement in symptoms. For
rheumatologists and patients, attributes related
to treatment benefits are key drivers. Mode of
administration has also been identified as a
decision driver both for RA patients and
rheumatologists. This result supports findings
of previous studies that show that mode of
administration (route and frequency) has a
strong impact on patients’ decisions, with oral
administration being the most preferred
[17, 19, 39]. Few studies have studied the
influence of onset of treatment action on
treatment decision-making [46]. Our results
suggested that a faster time for the drug to start
working is preferred, and this attribute may
impact treatment selection, mainly for
rheumatologists.
Other studies available in the literature
identified cost [20, 40] and safety [17, 19, 20, 43]
as main drivers of treatment selection. How-
ever, in our study, additional treatment cost
and safety seemed to be less valued, with these
attributes being the ones with the least relative
importance. One of the possible reasons for the
discrepancy observed in relation to the impor-
tance of cost in decision-making is the magni-
tude of the difference in costs proposed in the
Fig. 4 RA patients’ current and expected role in the decision-making process
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DCE. In our study, the additional cost ranged
from €0 to €50/month, while in previous studies
the cost ranged from €500 to €1500/month [20]
or from €0 to a threefold increase on health care
taxes (€260/month) [40]. Regarding safety, dif-
ferences may be due to the attributes used to
describe safety in previous studies (‘probability
of suffering serious infections’ [20], ‘generalized
adverse events’ [20, 40], ‘local adverse events’
[20], ‘reactions at the site of drug administra-
tion’ [40], ‘to stop the medication due to a side
effect by 6 months’ [43], ‘chance of serious
treatment reaction’ [18, 19] or ‘mild treatment
reaction’ [18]), which varied from the ones used
in this survey (‘percentage of patients that suffer
severe or mild adverse events’) and may be
interpreted in a different way. The lesser
importance attached to safety attributes may
also be explained by the inclusion of the ‘opti-
mal QoL’ concept of the lack of side effects.
The information provided by preferences
studies is not only relevant to improving health
decision-making, but can also be useful for
defining new drug development strategies,
more closely aligned with patients’ preferences.
Preference studies conducted during preclinical
development may contribute to seeking early
patient input on what outcomes are important;
during clinical trial design they may help define
patient-relevant endpoints and study enrol-
ment criteria; or in post-market approval stud-
ies, they may support the formulation of
product communication and marketing strate-
gies [47].
Shared decision-making (SDM) is the pinna-
cle of patient-centered care [48]. SDM increases
patient knowledge, reduces anxiety over the
care process and improves health outcomes [49]
by ensuring that medical care better aligns with
patients’ preferences and values. The results of
the study highlighted that RA patients were
willing to be involved in treatment decision-
making. Although most of them are involved in
the decision-making process, nearly 30%
maintain a passive attitude, with the rheuma-
tologist being the one who makes the decision
for them. The use of patient decision aids (PDA)
in RA may help rheumatologists to involve
patients in decision-making by providing
detailed information related to the disease and
its treatment options and guiding patients
through this process [50]. Since PDA provide
detailed information about the therapeutic
options, its use in clinical practice would cover
the demand for more information on thera-
peutic options found in the study.
This study has some limitations, some of
which are inherent to its design. First, although
DCE is the recommended approach and is
widely used to assess patient preferences for
treatment characteristics, real-world treatment
decision-making may differ from the stated
choices provided during DCE because of the
influence of treatment attributes that were not
included in the study as well as other influences
on decision making such as lifestyle or family
environment. Therefore, although the attri-
butes presented were confirmed as being the
most relevant for treatment decision-making in
RA, it cannot be excluded that attributes not
included may also be relevant and play a role in
treatment decision-making. Moreover, there is
some uncertainty associated with the interpre-
tation by patients of the attributes presented
within the scenarios, mainly time with optimal
QoL and onset of treatment action, and how it
may affect the results. Finally, since RA patients
were invited to participate by a Patient Advo-
cacy Group, they may not be representative of
the RA population and limitations in the gen-
eralizability of results cannot be excluded.
CONCLUSIONS
Our results provide knowledge related to
patient and rheumatologist preferences for
treatment, showing some differences between
both perspectives. For rheumatologists, in
addition to efficacy, treatment mode of
administration and time to onset of action are
decision-making drivers. For patients, efficacy
defined as time with optimal QoL and treat-
ment mode of administration are determinants
in treatment selection.
The knowledge of patients’ preferences and
the evidence that patients are willing to be
involved in treatment decision-making that
have been gained by this study may contribute
Adv Ther (2020) 37:1479–1495 1491
to and facilitate the adoption of a patient-cen-
tered care model.
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